Showing results (51-60 of 81) with videos related to
Sort By:
Pageof 9
American Journal of Surgery|February 1, 2016
Association of sentinel lymph node diameter with melanoma metastasisJustin Merkow, Alessandro Paniccia, Edward Jones, et al.Investigational New Drugs|January 20, 2010
A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancerQing Zhou, Daniel Gustafson, Sujatha Nallapareddy, et al.The Lancet. Rheumatology|May 10, 2026
Efficacy and safety of enpatoran, a Toll-like receptor 7/8 inhibitor, in patients with skin manifestations of cutaneous lupus erythematosus or systemic lupus erythematosus: findings from Cohort A of a multicentre, international, double-blind, placebo-controlled, dose-finding phase 2 trialEric F Morand, Victoria P Werth, Joerg Wenzel, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trialKazuo Koyanagi, Steven J O'Day, Rene Gonzalez, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2006
Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patientsKazuo Koyanagi, Steven J O'Day, Rene Gonzalez, et al.Lancet (London, England)|May 10, 2026
Enpatoran, a Toll-like receptor 7/8 inhibitor, in moderate-to-severe systemic lupus erythematosus: findings from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trialEric F Morand, Maria Dall'Era, Jorge Sanchez-Guerrero, et al.The Lancet. Oncology|February 26, 2018
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialMichele Maio, Karl Lewis, Lev Demidov, et al.Cancers|August 23, 2020
A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal MelanomaMerve Hasanov, Matthew J Rioth, Kari Kendra, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2022
ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 StudyMelissa Johnson, Arkadiusz Z Dudek, Ammar Sukari, et al.European Journal of Cancer (Oxford, England : 1990)|November 10, 2019
Health-related quality of life in patients with fully resected BRAFV600 mutation-positive melanoma receiving adjuvant vemurafenibDirk Schadendorf, Anna Maria Di Giacomo, Lev Demidov, et al.Pageof 9